Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Sponsor: Novartis Pharmaceuticals
Terminated
Due to slow accrual
Other terminated trials from Novartis Pharmaceuticals
Other Acute Lymphoblastic Leukemia trials with similar outcome
A PHASE2 clinical study on Acute Lymphoblastic Leukemia and Leukemia, B-Cell, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 12 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jul 2018 — May 2019 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
- Spectrum Pharmaceuticals, Inc
- St. Jude Children's Research Hospital
For direct contact, visit the study record on ClinicalTrials.gov .